This content is machine translated Chronic spontaneous urticaria When antihistamines are not enough – ligelizumab soon available in addition to omalizumab? The biologic omalizumab has empirically well-documented efficacy and safety and is considered the treatment of choice in international guidelines for cases of chronic spontaneous urticaria with inadequate response to antihistamines.…
